<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857727</url>
  </required_header>
  <id_info>
    <org_study_id>Dex Peds 08-088</org_study_id>
    <nct_id>NCT00857727</nct_id>
  </id_info>
  <brief_title>Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children</brief_title>
  <acronym>DexPeds</acronym>
  <official_title>Use of Dexmedetomidine for Emergence Delirium in Children Undergoing General Anesthesia for Endovascular Interventional Neuroradiologic Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emergence delirium (ED) from general anesthesia posts risk and harm to pediatric population
      undergo general anesthesia. The purpose of the study is to compare the use of dexmedetomidine
      versus placebo in reducing the incidence and severity of ED in a pediatric neurosurgical
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emergence delirium from general anesthesia is a common problem in the pediatric population
      with a reported incidence of up to 80%. In addition to being jarring to children and their
      parents, ED can cause significant physical harm, particularly to the surgical site. ED is
      also associated with accidental removal of surgical dressings and drains, intravenous and
      intra-arterial catheters, increased nursing care, extended recovery room stays, and delayed
      reunion with parents. Emergence delirium is especially associated with sevoflurane, the most
      commonly used inhalation anesthetic in pediatrics. At present, there is no single definition
      of pediatric ED because of its heterogeneous clinical presentation. It has been described as
      an acute phenomenon in which the child is irritable, uncompromising, uncooperative,
      incoherent, and inconsolably crying, moaning, kicking or thrashing. Typically, these children
      do not recognize or identify familiar objects or people, and often exhibit combative
      behavior. Although ED is a self-limiting phenomenon, it is especially dangerous in the
      interventional neuroradiologic patient whose femoral artery has been catheterized and must be
      kept immobile in the immediate post-operative period. These patients also have multiple
      intravenous and intra-arterial catheters which can be dislodged during an episode of ED.
      Numerous pharmacologic agents including benzodiazepines, opioids, ketamine, and clonidine,
      have been studied as prophylactic agents for ED but have met with varying success. Promising
      results with the α-2 adrenergic agonist clonidine, have spurred interest in a new α-2
      adrenergic agonist, dexmedetomidine.

      Dexmedetomidine is highly selective for the 2A subtype of the central presynaptic α-2
      adrenergic receptor which is associated with sedation and analgesia. It is currently approved
      for use in adults as a sedative agent in intensive care units but has been used in myriad
      other ways for sedation. As a sedative, dexmedetomidine is unusual in that it does not
      depress respiratory drive because its actions are not mediated by the GABA-mimetic system.
      The quality of sedation produced by dexmedetomidine is unique, and has been described as
      &quot;cooperative sedation,&quot; in which patients can interact with healthcare providers and follow
      verbal commands. This particular sedation profile permits a patient to be comfortably
      sedated, yet cooperate for an accurate neurological exam. The most extreme example of this is
      the awake craniotomy, in which a patient undergoes a neurological examination during surgery.
      In addition to being sedative, dexmedetomidine is also analgesic and suppresses shivering,
      making it especially useful in the perioperative period.

      There have been studies suggesting a use for dexmedetomidine in ED yet none have examined its
      use in the pediatric neurosurgical population. Treatment of ED in pediatric neurosurgical
      patients involves balancing the need for smooth emergence with the need for accurate
      neurological exams. Benzodiazepines and opioids are currently used to treat ED but are
      long-acting, interfere with neurological exams, and carry the risks of respiratory
      depression, nausea, vomiting, and acute tolerance. Dexmedetomidine provides an alternative to
      current treatment modalities for ED, which does not interfere with neurological exams.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Emergence Delirium</measure>
    <time_frame>15-45 minutes post-op</time_frame>
    <description>Emergence Delirium (ED) during the 15-45min. post-op period as assessed by the Cole Score. (Cole Score 3-5 = ED). The Cole Scale is an ordinal ranking of ED (1=sleeping; 2=awake, calm; 3=irritable, crying; 4=inconsolable, crying; 5=severe restlessness, disorientation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate and Pulse Oximetry) Will be Continuously Monitored in the PICU</measure>
    <time_frame>24 hours</time_frame>
    <description>Vital signs were not collected as part of research study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Anesthesia</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Surgery</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Study Drug</measure>
    <time_frame>Day 1</time_frame>
    <description>Total Study Drug used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sevoflurane</measure>
    <time_frame>Day 1</time_frame>
    <description>Total Drug used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Propofol</measure>
    <time_frame>Day 1</time_frame>
    <description>Total Drug used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Fentanyl</measure>
    <time_frame>Day 1</time_frame>
    <description>Total Drug used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Agitation</condition>
  <condition>Anesthesia</condition>
  <condition>Pediatrics</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline IV solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg</description>
    <arm_group_label>Drug</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Given by a continuous infusion</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Phosphate buffered saline</other_name>
    <other_name>PBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children age 6 months through 17 years of age undergoing interventional
             neuroradiologic procedures at our hospital under general anesthesia

          -  Patients classify as an ASA (American Society of Anesthesiologists) I-III

          -  Have not received anesthetic for over 30 days from previous procedures

        Exclusion Criteria:

          -  Receiving digoxin therapy from the study

          -  Severe congestive heart failure or pulmonary hypertension requiring vasodilators

          -  Disease processes other than that associated with their intracranial pathology, such
             as hepatic or renal dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jolie Narang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Blaine Easley R, Brady KM, Tobias JD. Dexmedetomidine for the treatment of postanesthesia shivering in children. Paediatr Anaesth. 2007 Apr;17(4):341-6.</citation>
    <PMID>17359402</PMID>
  </reference>
  <reference>
    <citation>Isik B, Arslan M, Tunga AD, Kurtipek O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. Paediatr Anaesth. 2006 Jul;16(7):748-53. Erratum in: Paediatr Anaesth. 2006 Jul;16(7):811.</citation>
    <PMID>16879517</PMID>
  </reference>
  <reference>
    <citation>Guler G, Akin A, Tosun Z, Ors S, Esmaoglu A, Boyaci A. Single-dose dexmedetomidine reduces agitation and provides smooth extubation after pediatric adenotonsillectomy. Paediatr Anaesth. 2005 Sep;15(9):762-6.</citation>
    <PMID>16101707</PMID>
  </reference>
  <reference>
    <citation>Ibacache ME, Muñoz HR, Brandes V, Morales AL. Single-dose dexmedetomidine reduces agitation after sevoflurane anesthesia in children. Anesth Analg. 2004 Jan;98(1):60-3, table of contents.</citation>
    <PMID>14693585</PMID>
  </reference>
  <reference>
    <citation>Walker J, Maccallum M, Fischer C, Kopcha R, Saylors R, McCall J. Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res. 2006 Mar-Apr;27(2):206-10.</citation>
    <PMID>16566567</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <results_first_submitted>March 4, 2016</results_first_submitted>
  <results_first_submitted_qc>November 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2018</results_first_posted>
  <last_update_submitted>November 23, 2018</last_update_submitted>
  <last_update_submitted_qc>November 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Emergence Delirium</keyword>
  <keyword>Agitation</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Emergence Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>33 children undergoing general anesthesia for endovascular interventional procedures. 28 patients provided complete data sets.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Drug</title>
          <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Normal Saline IV solution - Given by a continuous infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug</title>
          <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Normal Saline IV solution - Given by a continuous infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="2.6"/>
                    <measurement group_id="B2" value="4.2" spread="2.7"/>
                    <measurement group_id="B3" value="4.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Emergence Delirium</title>
        <description>Emergence Delirium (ED) during the 15-45min. post-op period as assessed by the Cole Score. (Cole Score 3-5 = ED). The Cole Scale is an ordinal ranking of ED (1=sleeping; 2=awake, calm; 3=irritable, crying; 4=inconsolable, crying; 5=severe restlessness, disorientation).</description>
        <time_frame>15-45 minutes post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Normal Saline IV solution - Given by a continuous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergence Delirium</title>
          <description>Emergence Delirium (ED) during the 15-45min. post-op period as assessed by the Cole Score. (Cole Score 3-5 = ED). The Cole Scale is an ordinal ranking of ED (1=sleeping; 2=awake, calm; 3=irritable, crying; 4=inconsolable, crying; 5=severe restlessness, disorientation).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate and Pulse Oximetry) Will be Continuously Monitored in the PICU</title>
        <description>Vital signs were not collected as part of research study.</description>
        <time_frame>24 hours</time_frame>
        <population>data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Normal Saline IV solution - Given by a continuous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate and Pulse Oximetry) Will be Continuously Monitored in the PICU</title>
          <description>Vital signs were not collected as part of research study.</description>
          <population>data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Normal Saline IV solution - Given by a continuous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="7.3"/>
                    <measurement group_id="O2" value="18.5" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Anesthesia</title>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Normal Saline IV solution - Given by a continuous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Anesthesia</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" spread="71"/>
                    <measurement group_id="O2" value="215" spread="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Surgery</title>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Normal Saline IV solution - Given by a continuous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Surgery</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="43"/>
                    <measurement group_id="O2" value="86" spread="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Study Drug</title>
        <description>Total Study Drug used</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Normal Saline IV solution - Given by a continuous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Total Study Drug</title>
          <description>Total Study Drug used</description>
          <units>mcg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.32"/>
                    <measurement group_id="O2" value="1.43" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sevoflurane</title>
        <description>Total Drug used</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Normal Saline IV solution - Given by a continuous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sevoflurane</title>
          <description>Total Drug used</description>
          <units>ml/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="1.38"/>
                    <measurement group_id="O2" value="6.80" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Propofol</title>
        <description>Total Drug used</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Normal Saline IV solution - Given by a continuous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Total Propofol</title>
          <description>Total Drug used</description>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="1.28"/>
                    <measurement group_id="O2" value="2.41" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fentanyl</title>
        <description>Total Drug used</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Normal Saline IV solution - Given by a continuous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fentanyl</title>
          <description>Total Drug used</description>
          <units>mcg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.79"/>
                    <measurement group_id="O2" value="2.36" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Two adverse events were noted requiring unblinding</desc>
      <group_list>
        <group group_id="E1">
          <title>Drug</title>
          <description>Dexmedetomidine - An initial dose, given one hour prior to extubation of 1.0 µg/kg over 20 minutes, followed by a continuous infusion at 0.5 µg/kg/hour, continuing for 30 minutes following extubation.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Normal Saline IV solution - Given by a continuous infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Severe bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive sedation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Methodology used cannot determine whether undescribed prolonged effect of DEX is related to the DEX or to increased activity levels in the placebo group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jinu Kim</name_or_title>
      <organization>Mount Sinai St. Luke's</organization>
      <phone>212-523-6121</phone>
      <email>JiKim@chpnet.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

